By Steve SearsGoldman Sachs is telling clients to hedge the bio-technology sector in anticipation of a sharp decline. Early Monday, the bank told clients to buy SPDR S&P Biotech ETF (XBI) December $230 puts. During the pre-market, the ETF was priced at $255, and the put was at $15.50.
SSPL via Getty Images
“These puts are about 10% out-of-the-money and cost about […]
Massive decline in technology stocks following earnings releases from Apple and Microsoft dragged major benchmarks to negative territory for the second-consecutive day. Meanwhile, another slump in oil prices also weighed on energy shares, which in turn had a negative impact on markets. However, encouraging existing home sales data boosted housing stocks on Wednesday.For a look at the issues currently facing […]
Hopes of Greece and its creditors reaching a deal later this week helped benchmarks end higher on Monday. Greece has submitted new fiscal proposals to avert a default. Separately, the Nasdaq closed at an all-time high lifted by gains in biotech stocks.For a look at the issues currently facing the markets, make sure to read today’s Ahead of Wall Street […]
Setback in bailout talks between Greece and its creditors over the weekend continued to negatively impact benchmarks on Tuesday. The lack of progress in Greek debt talks raised fears among investors of a possible default by Greece and the country’s exit from the Eurozone. Meanwhile, manufacturing activity worsened slightly for New York manufacturers and decline in U.S. industrial production in […]
Benchmarks ended Tuesday’s choppy trading session almost unchanged, with the Dow Jones Transportation Average nearing correction territory. The transportation index took a beating mostly due to a drop in airline stocks. The Nasdaq finished in negative territory dragged down by decline in biotech stocks, but the S&P 500 ended in the green boosted by gains in consumer staples and financial […]
Benchmarks ended the last trading day of the week in the red following Janet Yellen’s comments that it would be appropriate to raise interest rates sometime this year. Yellen said the economy is well positioned to grow even if weak economic data had indicated the economy was not on a solid footing. Meanwhile, an increase in consumer price index raised […]
Benchmarks ended mixed yesterday after Fed minutes showed officials looked past a June rate hike amid slow economic growth. While the S&P 500 and Dow ended in negative territory, Nasdaq ended in the green boosted by gains in biotech stocks. These three benchmarks had briefly touched their respective closing highs before settling lower.For a look at the issues currently facing […]
Benchmarks ended the last trading session of the month in the red dragged by losses in technology and biotechnology stocks. While, decline in Apple’s shares weighed on the technology sector, Celegen’s lower-than-expected quarterly revenues had a negative impact on biotech shares. Yesterday’s losses were broad based with all 10 sectors of the S&P 500 ending in the red and 27 […]
Biotech stocks have been surging since their mid-March plunge (back below the 50DMA), but it appears that is at an end as XBI – the SPDR Biotech ETF – is now down almost 7% from Friday’s highs on heavy volume (and back below the 50DMA once again).Which has smashed XBI back below its 50DMA on very heavy volume..This is a […]
Over the course of this long bull market, biotech stocks have been very, very good for their owners. Perhaps too good. Investors have shown such rabid enthusiasm for biotechs—especially small, unproven companies that have yet to bring a drug to market—that some observers are using another b word to describe the high-flying sector: bubble.See Also: 8 Stocks Under $10 Worth […]
